The most recent entrant to the WHO’s list is NB.1.8.1, derived from recombinant ancestor XDV.1.5.1. With multiple mutations in its spike protein, NB.1.8.1 is being closely observed for its potential to escape immune responses.More than five years since COVID-19 was declared a pandemic, the virus is far from gone. While global headlines may no longer be dominated by daily case counts, SARS-CoV-2—the virus responsible for COVID-19—continues to evolve, adapt, and spread in communities worldwide. In May 2025, a new wave of variants is quietly shaping the trajectory of the virus and prompting renewed concern among scientists and health professionals.Viruses are, by nature, constantly mutating. As SARS-CoV-2 moves from person to person, random genetic changes—known as mutations—accumulate. Most mutations are harmless, but some enhance the virus’s ability to spread, evade immunity, or cause severe illness.When a group of mutations significantly alters the virus's behavior, it is classified as a variant. These variants are then grouped by the World Health Organization (WHO) and CDC into three broad categories:Variants Under Monitoring (VUM)Variants of Interest (VOI)Variants of Concern (VOC)This classification is vital for public health responses, vaccine development, and treatment planning.Current Variants Circulating in May 2025According to global health monitoring systems, the major COVID-19 variants circulating in May 2025 include:KP.3KP.3.1.1LB.1XECLP.8.1NB.1.8.1Notably, all of these are descendants of Omicron, specifically from the lineage KP.1.1.3, itself a subvariant of JN.1—the dominant variant during the winter surge of 2023–2024.COVID-19 VARIANTFEATURESYMPTOMSKP.3KP.3 belongs to a cluster of Omicron descendants collectively referred to as FLiRT variants. This group also includes KP.2 (the prior dominant variant in the U.S.) and KP.1.1. Though KP.3 hasn’t demonstrated drastically different clinical outcomes, it continues to be the most prevalent variant across the U.S. and parts of Europe.Fever or chills, Cough, Shortness of breath, Fatigue, Loss of taste or smell, Sore throat, Diarrhea and nauseaKP.3.1.1A sublineage of KP.3, KP.3.1.1 is emerging as a significant global variant. It is now the most common variant among the JN.1-derived strains, contributing to sustained hospital visits and positive test rates, especially in at-risk age groups.Although not more severe in symptoms, its high transmissibility raises concerns for immunocompromised individuals and communities with low vaccination rates.LB.1Ranked third among the current U.S. variants, LB.1 has caught attention for anecdotal reports of particularly severe sore throats. It is, again, part of the FLiRT family and a direct descendant of JN.1.Intense sore throat, Fatigue, nasal congestion, FeverXECXEC is different from its peers—it's a recombinant variant, meaning it emerged from the blending of two separate Omicron strains, KS.1.1 and KP.3.3, within a single infected individual.High fever, Muscle aches, Sore throat, Dry cough, Extreme tirednessLP.8.1First identified in July 2024 and now labeled a Variant Under Monitoring by the WHO, LP.8.1 has demonstrated significant growth in multiple countries. Continuous cough, Loss of taste or smell, Shortness of breath, Muscle aches, Gastrointestinal discomfortNB.1.8.1The most recent entrant to the WHO’s list is NB.1.8.1, derived from recombinant ancestor XDV.1.5.1. With multiple mutations in its spike protein, NB.1.8.1 is being closely observed for its potential to escape immune responses.Fever, Dry cough, Sore throat, Headache, Mild gastrointestinal issuesCan COVID-19 Tests Identify the Variant?Most standard COVID-19 tests (PCR or antigen) only detect whether the virus is present—not which variant you’ve contracted. For that, scientists rely on genomic sequencing, which is typically used for public health tracking rather than individual diagnosis.So if you test positive, assume you may have one of the circulating variants and act accordingly.Do the Current Vaccines Work?While some variants can partially evade immunity, vaccination remains one of the most effective ways to reduce severe illness, hospitalization, and death.Current recommendations from public health agencies include:Getting the updated bivalent or variant-specific boosterWearing masks in crowded indoor settingsAvoiding high-risk environments, especially if you're immunocompromisedPracticing good hand hygieneIsolating if you feel sickAs one infectious disease expert put it, “We still have a lot of virus in circulation—masks, vaccines, and vigilance continue to be our best tools.”In May 2025, the COVID-19 landscape continues to shift. While symptoms largely mirror earlier waves, the evolving nature of variants like KP.3.1.1, LB.1, and NB.1.8.1 highlights the importance of surveillance, booster uptake, and public awareness.